Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04514484
Title Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

Advanced Solid Tumor

prostate carcinoma

hepatocellular carcinoma

transitional cell carcinoma

differentiated thyroid gland carcinoma

lung small cell carcinoma

renal cell carcinoma

thyroid gland medullary carcinoma

lung non-small cell carcinoma

Kaposi's sarcoma

ovarian cancer

head and neck cancer

triple-receptor negative breast cancer



Cabozantinib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.